CHICAGO, April 19, 2017 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) has announced its biennial PFF Summit 2017, an international conference addressing pulmonary fibrosis (PF), a devastating and deadly disease resulting from progressive scarring of the lungs.
The PFF Summit invites medical professionals, researchers, industry representatives, patients, caregivers, transplant recipients and those who have lost a loved one to join informative and collaborative sessions highlighting the most current developments in the research and treatment of PF. The conference will take place from November 9-11 at the Omni Nashville Hotel in Nashville, Tennessee. The PFF Summit 2017 is sponsored in part by Boehringer Ingelheim and Genentech, a Roche company.
"This year's conference offers our community an extraordinary opportunity to engage directly with leading researchers and physicians," said Gregory P. Cosgrove, M.D., Chief Medical Officer at the PFF. "Our goal is to foster a collaborative environment to improve education and awareness of pulmonary fibrosis and to identify new approaches to treat, and ultimately cure, this disease."
For the first time, the Summit will feature dedicated sessions for newly diagnosed patients and family members, those who have been living with PF and those who have lost a loved one to the disease and lung transplant recipients. Sessions will address the genetics of pulmonary fibrosis, stem cell and cell-based therapy, symptom management, tips on living with oxygen therapy, understanding the processes for research and clinical trials, and more. A peer-supported roundtable discussion will cover financial topics such as Medicare/Medicaid, estate planning and insurance issues, preparing for an effective doctor visit and dealing with caregiver burnout. The full program is available at pffsummit.org/program.html.
The PFF Summit 2017 presents a three-day Continuing Medical Education (CME) and Continuing Education (CE) program for physicians, researchers, registered nurses, respiratory therapists, pharmacists and allied health professionals. Concentrating on the science and disease mechanisms of PF, these sessions will examine genetics, environmental influences, and advances in diagnosis and therapeutics.
Plenary sessions for all attendees will include presentations on the promise of genetics and personalized medicine in PF and maximizing the impact of available therapies in idiopathic pulmonary fibrosis.
Academic and industry researchers are invited to submit abstracts of their scientific research which will be presented during the welcome reception on Thursday, November 9. The call for abstracts opens June 15 with a deadline of August 1. All abstracts must be submitted through the online application system, proposalCENTRAL, which is available at https://proposalcentral.altum.com/.
About the Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation mobilizes people and resources to provide access to high quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives. The PFF collaborates with physicians, organizations, patients, and caregivers worldwide. The Pulmonary Fibrosis Foundation has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The PFF Summit 2017, its fourth biennial international health care conference will be held from November 9-11, 2017 in Nashville, Tennessee. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733) or 312.587.9272 from outside of the US.
CONTACT: Dorothy Coyle
SOURCE The Pulmonary Fibrosis Foundation